Fungal Skin Infections in Cutaneous T-cell Lymphoma Patients under Mogamulizumab Treatment

Authors

  • Susanne Melchers Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/University of Heidelberg, Mannheim, Germany; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany; Section of Immune Dermatology, Allergy and cutaneous lymphoma, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany https://orcid.org/0000-0002-6456-2681
  • Marlis Gerigk Institute of Medical Microbiology and Hygiene, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany
  • Maren Hedke Institute of Clinical Chemistry, University Medicine Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
  • Christel Weiß Department of Medical Statistics and Biomathematics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
  • Jan P. Nicolay Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/University of Heidelberg, Mannheim, Germany; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany; Section of Immune Dermatology, Allergy and cutaneous lymphoma, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany https://orcid.org/0000-0003-0220-0551

DOI:

https://doi.org/10.2340/actadv.v106.adv-2026-0693

Keywords:

CCR4, cutaneous lymphoma, tinea

Downloads

Download data is not yet available.

References

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia 2022; 36: 1720–1748. DOI: https://doi.org/10.1038/s41375-022-01620-2

Dobos G, Pohrt A, Ram-Wolff C, Lebbé C, Bouaziz JD, Battistella M, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers 2020; 12: 12. DOI: https://doi.org/10.3390/cancers12102921

Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. Br J Dermatol 2018; 179: 1322–1328. DOI: https://doi.org/10.1111/bjd.17073

Martin SJ, Duvic M. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol 2012; 51: 1195–1198. DOI: https://doi.org/10.1111/j.1365-4632.2011.05204.x

Lakhani SJ, Bilimoria F, Lakhani JD. Adverse effects of steroid use in dermatophytic infections: a cross sectional study. J Integr Health Sci 2017; 5: 63. DOI: https://doi.org/10.4103/2347-6486.240248

Priyanka A N, K Kaviarasan P, Kannambal K, Poorana B, AbhiramiC. Clinicoepidemiological profile of steroid modified dermatophytosis following abuse of irrational combination of topical corticosteroid containing preparations (ICSP). IJCED 2020; 6: 318–324. DOI: https://doi.org/10.18231/j.ijced.2020.064

Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - update 2023. Eur J Cancer 2023; 195: 113343. DOI: https://doi.org/10.1016/j.ejca.2023.113343

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192–1204. DOI: https://doi.org/10.1016/S1470-2045(18)30379-6

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140: 1229–1253. DOI: https://doi.org/10.1182/blood.2022015851

Allen PB, Switchenko J, Ayers A, Kim E, Lechowicz MJ. Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL). Leuk Lymphoma 2020; 61: 2652–2658. DOI: https://doi.org/10.1080/10428194.2020.1779259

Wu S, Xu Y, Yang L, Guo L, Jiang X. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Front Immunol 2023; 14: 1294416. DOI: https://doi.org/10.3389/fimmu.2023.1294416

Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, et al. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: a multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023; 37: 1777–1784. DOI: https://doi.org/10.1111/jdv.19134

Molloy K, Vico C, Ortiz-Romero PL, Scarisbrick JJ. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome. Br J Dermatol 2021; 184: 978–981. DOI: https://doi.org/10.1111/bjd.19720

Jfri A, Virgen CA, Tawa M, Giobbie-Hurder A, Kupper TS, Fisher DC, et al. Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience. J Am Acad Dermatol 2023; 89: 1044–1047. DOI: https://doi.org/10.1016/j.jaad.2023.05.082

Assaf C, Booken N, Dippel E, Dobos G, Eich HT, Klemke CD, et al. Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany. J Dtsch Dermatol Ges 2025; 23: 341–354. DOI: https://doi.org/10.1111/ddg.15639

Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect 2018; 24 Suppl 2: S83–S94. DOI: https://doi.org/10.1016/j.cmi.2018.03.022

Downloads

Published

2026-07-28

How to Cite

Melchers, S., Gerigk, M., Hedke, M., Weiß, C., & Nicolay, J. P. (2026). Fungal Skin Infections in Cutaneous T-cell Lymphoma Patients under Mogamulizumab Treatment. Acta Dermato-Venereologica, 106, adv–2026. https://doi.org/10.2340/actadv.v106.adv-2026-0693

Issue

Vol. 106 (2026)

Section

Short Communication

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC